Sativa appoints Chief Financial Officer and Director

By in
156

Press Release                                                                                                                              Thursday, 30th August 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC

 (“Sativa” or the “Company”)

Sativa appoints Chief Financial Officer and Director

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has appointed Joseph Colliver FCA as Chief Financial Officer and a Director of the Company. 

Geremy Thomas, founder and Chief Executive Officer of Sativa, said: “With four investments to date and a pipeline of potential investments at varying stages of review, the Company needs an experienced, strategically-thinking full-time finance head. 

“Joseph brings a depth of international experience including from his time at Kantar Consulting, part of WPP plc, where he advised clients on developing commercial capability.  Coupled with his experience as Chief Financial Officer at Kantar Futures, a consultancy business with a $32 million turnover, his role as Global Commercial Director of WPP’s Kantar subsidiary Taylor Nelson Sofres, a $1.8 billion turnover marketing agency, and his Mazars’ Accountancy training, Joseph has a lot to offer the ever-expanding Sativa.” 

Joseph Colliver (aged 38)

Joseph is a qualified Chartered Accountant with significant management consulting experience.  Before joining Sativa, Joseph was a Director of Consulting at Kantar Consulting, part of WPP plc (“WPP”) which advises Retail, Sales and Shopper clients on enhancing their commercial capability and the commercial competency of their staff.  Prior to this, Joseph was Chief Financial Officer and a senior board member at WPP’s Kantar Futures, which advises its clients on enhancing profit through change and shaping strategy.  Here, Joseph was accountable for financial performance, managing a global finance team.  From 2012 – 2015 Joseph was Global Commercial Director of WPP’s Kantar subsidiary Taylor Nelson Sofres, a $1.8 billion turnover marketing agency.  

Before joining WPP, Joseph was an Audit Senior at Mazars LLP, where he qualified as an Accountant with the Institute of Chartered Accountants in England and Wales (ICAEW), being made a Fellow in 2018.  He gained a Geophysics BSc (Hons) 2:1 from Southampton University.

As at the date of this announcement, Joseph has been granted 3,350,000 share options in the Company at 1.5p. 

Joseph Colliver

Joseph has been a director or partner of the following companies/partnerships in the last five years:

Current Directorships and Partnerships

Past Directorships and Partnerships

 

Headlight Vision Limited

 

Henley Centre Headlight Vision Ltd

There is no further information relating to Joseph Colliver that is required to be disclosed pursuant to Paragraph 21, Appendix 1 of the NEX Exchange Growth Market – Rules for Issuers.

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company, Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil. 

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

54321
(0 votes. Average 0 of 5)